GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aceragen Inc (NAS:ACGN) » Definitions » Degree of Financial Leverage

Aceragen (Aceragen) Degree of Financial Leverage : -0.43 (As of Mar. 2023)


View and export this data going back to 1996. Start your Free Trial

What is Aceragen Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Aceragen's Degree of Financial Leverage for the quarter that ended in Mar. 2023 was -0.43. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for Aceragen's Degree of Financial Leverage or its related term are showing as below:

ACGN's Degree of Financial Leverage is not ranked
in the Biotechnology industry.
Industry Median: 0.96 vs ACGN: -0.43

Aceragen Degree of Financial Leverage Historical Data

The historical data trend for Aceragen's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aceragen Degree of Financial Leverage Chart

Aceragen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Degree of Financial Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.98 -890.48 0.02 1.21 0.06

Aceragen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 0.07 0.13 0.06 -0.43

Competitive Comparison of Aceragen's Degree of Financial Leverage

For the Biotechnology subindustry, Aceragen's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aceragen's Degree of Financial Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aceragen's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Aceragen's Degree of Financial Leverage falls into.



Aceragen Degree of Financial Leverage Calculation

Aceragen's Degree of Financial Leverage for the quarter that ended in Mar. 2023 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -8.757 (Mar. 2023) / -7.12 (Mar. 2022) - 1 )/( -22.804 (Mar. 2023) / -146.274 (Mar. 2022) - 1 )
=0.2299/-0.8441
=-0.27***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Aceragen  (NAS:ACGN) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Aceragen Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of Aceragen's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Aceragen (Aceragen) Business Description

Industry
Traded in Other Exchanges
N/A
Address
505 Eagleview Boulevard, Suite 212, Exton, PA, USA, 19341
Aceragen Inc is a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases. The company portfolio includes late-stage programs based on well-established biological principles that are developing to be inventive therapeutics capable of addressing the unmet medical needs of individuals living with rare diseases.
Executives
Vincent Milano director, officer: President & CEO C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341
Maxine Gowen director
Pillar Invest Corp director, 10 percent owner C/O PILLAR INVEST OFFSHORE SAL, STARCO CENTER, BLOC B FL3, OMAR DAOUK ST, BEIRUT M8 2020-3313
Atul Chopra 10 percent owner C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
John Clayton Taylor director, officer: Chief Executive Officer C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
Carl N Kraus officer: Chief Medical Officer C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
Andrew R Jordan officer: Chief Strategy Officer C/O GUILFORD PHARMACEUTICALS INC, 6611 TIBUTARY ST., BALTIMORE MD 21224
Daniel Salain officer: Chief Operating Officer C/O GRAYBUG VISION, INC., 275 SHORELINE DRIVE, SUITE 450, REDWOOD CITY CA 94065
Ronald J Wooten director
Nq Pof V Gp, Ltd. director, other: See Remarks 4208 SIX FORKS ROAD, SUITE 920, RALEIGH NC 27609
Novaquest Co-investment Fund Xv, L.p. director, other: See Remarks 4208 SIX FORKS ROAD, SUITE 920, RALEIGH NC 27609
John J. Kirby officer: V.P. of Finance, PFO & PAO C/O IDERA PHARMACEUTICALS, INC., 505 EAGLEVIEW BLVD., SUITE 212, EXTON PA 19341
Michael R Dougherty director C/O ADOLOR CORP, 700 PENNSYLVANIA DR, EXTON PA 19341
Elizabeth Ann Tarka officer: Chief Medical Officer 111 WAVERLY CIRCLE, PHOENIXVILLE PA 19460
Bryant David Lim officer: SVP & General Counsel C/O IDERA PHARMACEUTICALS, INC., 505 EAGLEVIEW BLVD., SUITE 212, EXTON PA 19341

Aceragen (Aceragen) Headlines